DESTREMAU, Marjolaine; CHAUSSADE, Hélène; HEMAR, Victor; BEGUET, Mathilde; BELLECAVE, Pantxika; BLANCHARD, Elodie; BARRET, Amaury; LABOURE, Gaelle; VASCO-MOYNET, Claire; LACASSIN, Flore; MORISSE, Eloïse; AGUILAR, Claire; LAFARGE, Xavier; LAFON, Marie-Edith; BONNET, Fabrice; ISSA, Nahéma; CAMOU, Fabrice

doi:10.1002/jmv.29603

Langue

Article de revue

Ce document a été publié dans

Journal of Medical Virology. 2024-04-01, vol. 96, n° 4, p. e29603

Résumé en anglais

This study aims to assess the safety, virological, and clinical outcomes of convalescent plasma transfusion (CPT) in immunocompromised patients hospitalized for coronavirus disease 2019 (COVID-19). We conducted a retrospective multicenter cohort study that included all immunosuppressed patients with COVID-19 and RNAemia from May 2020 to March 2023 treated with CPT. We included 81 patients with hematological malignancies (HM), transplants, or autoimmune diseases (69% treated with anti-CD20). Sixty patients (74%) were vaccinated, and 14 had pre-CPT serology >264 BAU/mL. The median delay between symptom onset and CPT was 23 days [13-31]. At D7 post-CPT, plasma PCR was negative in 43/64 patients (67.2%), and serology became positive in 25/30 patients (82%). Post-CPT positive serology was associated with RNAemia negativity (p < 0.001). The overall mortality rate at D28 was 26%, being higher in patients with non-B-cell HM (62%) than with B-cell HM (25%) or with no HM (11%) (p = 0.02). Patients receiving anti-CD20 without chemotherapy had the lowest mortality rate (8%). Positive RNAemia at D7 was associated with mortality at D28 in univariate analysis (HR: 3.05 [1.14-8.19]). Eight patients had adverse events, two of which were severe but transient. Our findings suggest that CPT can abolish RNAemia and ameliorate the clinical course in immunocompromised patients with COVID-19.< Réduire

Mots clés en anglais

Humans

COVID-19

Blood Component Transfusion

COVID-19 Serotherapy

Cohort Studies

Plasma

Hematologic Neoplasms

Immunocompromised Host

Viremia

URI

https://oskar-bordeaux.fr/handle/20.500.12278/201762

DOI

http://dx.doi.org/10.1002/jmv.29603

Unités de recherche

Bordeaux Population Health Research Center (BPH) - UMR 1219

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Convalescent plasma transfusion for immunocompromised viremic patients with COVID-19: A retrospective multicenter study.

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche